Press Releases
| All Releases | ||||||
|---|---|---|---|---|---|---|
 |
Dyax Corp. Announces First Quarter 2009 Financial Results Apr 22, 2009 |
81.7 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 22, 2009-- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the first quarter ended March 31, 2009. Dyax will host a webcast and conference call at 10 a.m. (ET) this morning to review the financial results and corporate progress for the quarter. Financial Results Total... |
||||||
|
Dyax Corp. to Host First Quarter 2009 Earnings Call and Webcast Apr 15, 2009 |
17.7 KB |
|
|||
|
CAMBRIDGE, Mass., Apr 15, 2009 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, April 22, 2009, to discuss its financial results and company progress for the first quarter ended March 31, 2009. Date: Wednesday, April 22, 2009... |
||||||
|
Dyax to Focus Resources on DX-88 Commercial Launch with Reduction in Force Mar 30, 2009 |
20.0 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 30, 2009-- Dyax Corp. (NASDAQ:DYAX) announced today that it is eliminating 60 positions, effective immediately, from various departments within the Company to focus its resources on the commercialization of its lead product candidate, DX-88. The reduction in force will result in savings that will allow the... |
||||||
|
Dyax Receives Complete Response Letter from FDA for DX-88 in Acute Attacks of Hereditary Angioedema Mar 26, 2009 |
22.1 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 26, 2009-- Dyax Corp. (NASDAQ:DYAX) announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) pertaining to the Company’s Biologic License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE)... |
||||||
|
Dyax Amends Loan Agreement with Cowen Healthcare Royalty Partners for an Additional $15 Million Mar 18, 2009 |
22.5 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 18, 2009-- Dyax Corp. (NASDAQ: DYAX) announced today that it has amended its existing loan agreement with Cowen Healthcare Royalty Partners, L.P. (“CHRP”) to receive an additional loan of $15 million (the “Tranche B Loan”). The Tranche B Loan will be secured by the Company’s p... |
||||||
|
Dyax Corp. Announces Fourth Quarter and Year End 2008 Financial Results Feb 25, 2009 |
24.5 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2009-- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the fourth quarter and year ended December 31, 2008. Dyax will host a webcast and conference call at 10 a.m. (ET) this morning to review the financial results and corporate progress for the quarter. Financial Results... |
||||||
|
Dyax Corp. to Host Fourth Quarter and Year End 2008 Earnings Call and Webcast Feb 18, 2009 |
17.8 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 18, 2009-- Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, February 25, 2009, to discuss its financial results and company progress for the fourth quarter and year ended December 31, 2008. Date: Wednesday, Februar... |
||||||
|
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications Feb 10, 2009 |
22.7 KB |
|
|||
|
CAMBRIDGE, Mass. & PARIS, Feb 10, 2009 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ: DYAX) and Fovea Pharmaceuticals, SA ("Fovea") announced today that they have entered into an exclusive license agreement for the development and commercialization of an ocular formulation of DX-88 for the treatment of retinal diseases. The license grants Fo... |
||||||
|
Dyax Announces Expansion of Antibody Discovery Collaboration with Biogen Idec Feb 5, 2009 |
21.2 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ:DYAX) announced today that they have expanded their antibody funded research and library license agreement with Biogen Idec (NASDAQ:BIIB) to include the discovery of additional antibody products identified using Dyax’s proprietary drug discovery technology, phage display. Dyax ... |
||||||
|
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema Feb 4, 2009 |
21.1 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ:DYAX) announced today that the U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Advisory Committee voted (6 yes, 5 no, 2 abstentions) in favor of approval of DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE). If approved, DX-88 will be the... |
||||||
|
Dyax Announces FDA Advisory Committee to Review DX-88 for Hereditary Angioedema Jan 13, 2009 |
20.5 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 13, 2009--Dyax Corp. (NASDAQ:DYAX) announced today that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee is scheduled to discuss the Company's Biologics License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE... |
||||||
|
FDA Accepts Filing and Grants Priority Review for DX-88 for Hereditary Angioedema Nov 21, 2008 |
20.2 KB |
|
|||
|
CAMBRIDGE, Mass., Nov 21, 2008 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ: DYAX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Biologics License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) and has designated the application for Pri... |
||||||
|
Dyax Corp. to Present at the Lazard Capital Markets Healthcare Conference Nov 12, 2008 |
17.4 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 12, 2008--Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax, will present at the Lazard Capital Markets 5th Annual Healthcare Conference, being held November 18-19 a... |
||||||
|
First-Ever Study Conducted Demonstrating Economic, Individual, and Societal Burden of Hereditary Angioedema Nov 10, 2008 |
24.6 KB |
|
|||
|
HONOLULU & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 10, 2008--Results of a ground-breaking study quantifying the economic, individual and societal burden of hereditary angioedema (HAE) bring to light the substantial direct and indirect costs of the disease on patients and society. The study reveals a compelling need for new and better therapi... |
||||||
|
Dyax Corp. to Present at the Credit Suisse Healthcare Conference Nov 6, 2008 |
17.3 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 6, 2008--Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax, will present at the Credit Suisse 2008 Annual Healthcare Conference, being held November 12-14 at the Arizona Biltmo... |
||||||
|
Dyax Corp. to Present at the Rodman & Renshaw Healthcare Conference Nov 5, 2008 |
17.3 KB |
|
|||
|
CAMBRIDGE, Mass., Nov 05, 2008 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax, will present at the Rodman & Renshaw 10th Annual Healthcare Conference, being held November 10-12 at The New Yo... |
||||||
|
Dyax Secures $50 Million Committed Equity Financing Facility Oct 30, 2008 |
19.8 KB |
|
|||
|
CAMBRIDGE, Mass., Oct 30, 2008 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX) announced today that it has entered into a committed equity financing facility under which it may sell up to $50 million of its common stock to Azimuth Opportunity, Ltd. over an 18-month period. The Company is not obligated to issue any shares to Azimuth under the $50 mil... |
||||||
|
Dyax Corp. Announces Third Quarter 2008 Financial Results Oct 22, 2008 |
23.0 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2008. Dyax will host a webcast and conference call at 10 a.m. (ET) this morning to review the financial results and corporate progress for the quarter. Financial Results Total revenues fo... |
||||||
|
Dyax Announces CEO Transition Plan Oct 20, 2008 |
19.9 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) announced today that Gustav A. Christensen, who joined Dyax as Executive Vice President and Chief Business Officer in April 2007, will succeed Henry E. Blair as President and Chief Executive Officer on January 1, 2009. Mr. Blair, who co-founded Dyax in 1989 and has served as Chairman, P... |
||||||
|
Dyax Corp. to Host Third Quarter 2008 Earnings Call and Webcast Oct 15, 2008 |
16.9 KB |
|
|||
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, October 22, 2008, to discuss its financial results and company progress for the third quarter ended September 30, 2008. Date: Wednesday, October 22, 2008 Time: 1... |
||||||
|
||||||
= add release to Briefcase
0.01 (-0.38)%
Briefcase
Email Alerts
IR Contacts
RSS Feeds
Mobile Investor